Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2336-2343

  Kisanga, Elton R ^a,b   Gjerde, Jennifer ^a   Guerrieri Gonzaga, Aliana ^c   Pigatto, Francesca ^c   Pesci Feltri, Adriana ^c   Robertson, Chris ^e   Serrano, Davide ^c   Pelosi, Giuseppe ^c   Decensi, Andrea ^c,d   Lien, Ernst A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; AMLODIPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DILTIAZEM; DRUG METABOLITE; ENALAPRIL; FLUOXETINE; KI 67 ANTIGEN; N DIDESMETHYLTAMOXIFEN; NICARDIPINE; NIFEDIPINE; NORTAMOXIFEN; SEX HORMONE BINDING GLOBULIN; SIMVASTATIN; SPIRONOLACTONE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TABLET; VAGINA DISCHARGE;

AGED; BREAST NEOPLASMS; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; RECEPTORS, ESTROGEN; SEX HORMONE-BINDING GLOBULIN; SMOKING; TAMOXIFEN; TIME FACTORS;

EID: 11144355178     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0538     Document Type: Article

References (60)

1. Winer EP, Hudis C, Burstein HJ, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-27.
2. Park, W-C, Jordan VC. Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention. Trends mol med 2002;8:82-8.
3. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
4. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
5. Cuzick J, Forbes J, Edwards R. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
6. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
7. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
8. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
9. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
10. Langan-Fahey SM, Douglass C, Tormey DC, Jordan VC. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 1990;26:883-8.
11. Bratherton DG, Brown CH, Buchanan R, et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal woman with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 1984; 50:199-205.
12. Peyrade F, Frenay M, Etienne MC, et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 1996;59:401-10.
13. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in Tamoxifen-treated breast cancer patients - findings from the national surgical adjuvant breast and bowel project (NSABP) b-14. J Nat Cancer Inst 1994;86:527-37.
14. Rutquist LE, Johansson H, Signomklao H, Johanssson U, Fornander T Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm breast cancer study group. J Natl Cancer Inst. 1995;87:645-51.
15. Clarke M, Collins R, Davies C, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
16. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-7.
17. Lien EA, Lonning PE. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treat Rev 2000;26:205-27.
18. Hu Y, Dehal SS, Hynd G, Jones GB, Kupfer D. CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes. Xenobiotica 2003;33:141-51.
19. Kivisto KT, Villikka K, Nyman L, Anttila M Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998;64:648-54.
20. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997;53: 171-8.
21. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997;57:3402-6.
22. Pasqualini JR, Sumida C Giambiagi N. Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem 1988;31(4B):613-43.
23. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 1982;16:1-13.
24. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90.
25. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antitrombin III. Cancer Res 1987;47:4517-9.
26. Kailajarvi M, Ahokoski O, Virtanen A, Salminen E, Irjala K. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. Anticancer Res 2000;20:1323-7.
27. Buckley, MM-T, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-90.
28. Lien EA, Johannessen DC, Aakvaag A, Lønning PE. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 1992;41: 541-3.
29. Lien EA, Ueland PM, Solheim E, Kvinnsland S. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography. Clin Chem 1987;33:1608-14.
30. Adam, H. K. A review of the pharmacokinetics and metabolism of "Nolvadex" (tamoxifen). In: RL Sutherland, Jordan VC, editors. Non-Steroidal Antioestrogens. Mol. Pharmacol. Antitumour Activity. London: Academic Press; 1981. p. 59-74.
31. Oken MM, Creech RH, Tormey DC, et al. National Cancer Institute Common Toxicity Criteria. Common Toxicity Criteria. Ed. 2. Bethesda: National Cancer Institute; 1999.
32. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991;51:4837-44.
33. Kisanga ER, Gjerde J, Schjott J, Mellgren G, Lien EA. Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 2003;84:361-7.
34. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989;49:2175-83.
35. Rowland, M, Tozer, TN. Clinical Pharmacokinetics: Concepts and Applications, Ed. 2. Philadelphia, PA: Lea & Febiger 1989. p. 380.
36. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000;39:49-75.
37. Lowry JA, Kearns GL, Abdel-Rahman SM, et al. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther 2003;73:209-22.
38. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000;28:125-30.
39. Gibson GG, Plant NJ, Swales KE, Ayrton A El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002;32:165-206.
40. Johnston SRD, Haynes BP, Sacks NPM, et al. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat 1993;28:241-50.
41. Johnston SRD, Haynes BP, Smith IE, et al. Aquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 1993;342:1521-2.
42. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 1980;64:761-4.
43. Milano G, Etienne MC, Frenay M, et al. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br J Cancer 1987;55:509-12.
44. Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose dose reduction. J Clin Oncol 1999;17:2633-8.
45. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002;30:608-12.
46. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
47. Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002;301:945-52.
48. Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002;32:863-78.
49. Cotreau MM, von Moltke LL, Harmatz JS, Greenblatt DJ. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology 2001;63: 210-9.
50. Taylor CM, Blanchard B, Zava DT. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 1984;44:1409-14.
51. Etienne MC, Milano G, Fischel JL, et al. Tamoxifen metabolism: pharmacokinetic and in vitro study. Br J Cancer 1989;60:30-5.
52. Fabian C, Tilzer L, Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: Correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 1981;2:381-90.
53. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982;42:317-23.
54. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984;44: 112-9.
55. de Lima GR, Facina G, Shida JY, et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003;39:891-8.
56. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 1988;48:2304-8.
57. Mauvais-Jarvis P, Baudot N, Castaigne D, Banzet P Kuttenn F. Trans-4-hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 1986;46: 1521-5.
58. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-64.
59. Barkhem T, Andersson-Ross C, Hoglund M, Nilsson S. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 1997;62:53-64.
60. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.